Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Exploring Injectable Scaffolded Spheroids for Nucleus Pulposus Therapy in Degenerated Intervertebral Discs

Balasubramanian RV., Muerner M., Kopinski-Grünwald O., Grad S., Fernández-Pérez J., Ovsianikov A.

Laboratory Study on Disc Degeneration, published in ACS Appl Mater Interfaces (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
ACS Appl Mater Interfaces (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41693133
PMCID
PMC12954655
DOI
10.1021/acsami.5c24306

Abstract (original English)

Cell-based therapies for intervertebral disc degeneration (IVDD) treatment face significant challenges, including cell damage from injection-induced shear stress and poor survival in the harsh, nutrient-depleted microenvironment of the intervertebral disc. To overcome these challenges, we developed scaffolded spheroids (S-SPH) by integrating human bone marrow-derived mesenchymal stem cell (hBMSC) spheroids (SPH) into microscaffolds (MS) produced via high-resolution 3D printing, thereby forming injectable tissue-building blocks. We optimized cell seeding density (∼2000 cells/spheroid) and MS fabrication parameters and induced nucleus pulposus (NP)-like differentiation using growth differentiation factor-5 (GDF5) under both normoxic and hypoxic, low-glucose conditions mimicking a healthy in vivo -like environment. S-SPH maintained high cell viability and produced abundant extracellular matrix under both culture conditions. They also upregulated key NP markers, including aggrecan (ACAN), keratin-18 (KRT18), and hypoxia-inducible factor-1α (HIF1α), which indicated successful NP-like differentiation. They also exhibited improved compressive properties approaching those of native human IVD and retained structural integrity and cell viability following injection through a 26G needle. When differentiated into an NP-like phenotype, S-SPH fused and retained a high viability upon injectio

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Spheroids, CellularMesenchymal Stem CellsHumansTissue EngineeringCell DifferentiationCell SurvivalHypoxia-Inducible Factor 1, alpha SubunitAggrecansTissue ScaffoldsIntervertebral Disc Degeneration

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research